Abstract Number: 065 • 2020 Pediatric Rheumatology Symposium
Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Temporomandibular joint (TMJ) arthritis is present in 40-96% of children with Juvenile Idiopathic Arthritis (JIA) (1). TMJ arthritis can be difficult to identify, treat,…Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium
Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…Abstract Number: 154 • 2020 Pediatric Rheumatology Symposium
T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common autoimmune arthritis in children. Polyarticular JIA and extended oligoarticular JIA both have genetic associations near genes…Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium
Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers
Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…Abstract Number: 070 • 2020 Pediatric Rheumatology Symposium
The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA wherein more than four joints are affected with arthritis; it is characterized by unpredictable…Abstract Number: 160 • 2020 Pediatric Rheumatology Symposium
CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Rationale: Juvenile idiopathic arthritis (JIA) is an inflammatory autoimmune disorder driven by dysfunction of the joint tissue and abnormal immune responses. As deep phenotyping…Abstract Number: 004 • 2020 Pediatric Rheumatology Symposium
Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort
Background/Purpose: PRINTO recently proposed preliminary JIA classification criteria to revise the International League of Associations for Rheumatology (ILAR) criteria. The stated aim was to obtain…Abstract Number: 074 • 2020 Pediatric Rheumatology Symposium
Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)
Background/Purpose: Patient outcomes and experiences are key components in the measurement of overall health outcomes in JIA and can be measured by validated PROMs and…Abstract Number: 164 • 2020 Pediatric Rheumatology Symposium
The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants
Background/Purpose: The JIA risk haplotypes, like those of other autoimmune diseases, are highly enriched for H3K4me1/H3K27ac histone marks, epigenetic features typically associated with functional enhancers.…Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium
Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…Abstract Number: 086 • 2020 Pediatric Rheumatology Symposium
Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis
Background/Purpose: Many patients are overwhelmed with the diagnosis of chronic childhood arthritis and require long-term treatments. Our objective was to develop a new, child and…Abstract Number: 165 • 2020 Pediatric Rheumatology Symposium
A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus
Background/Purpose: While genome-wide association studies have provided valuable information about genetic risk for juvenile idiopathic arthritis (JIA), we are still unable to determine the actual…Abstract Number: 017 • 2020 Pediatric Rheumatology Symposium
MyD88 S209R-Mediated Immune Dysregulation in Mouse Models of Arthritis
Background/Purpose: MYD88 is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-kB. We previously reported a heterozygous de novo mutation in MYD88 (S222R)…Abstract Number: 097 • 2020 Pediatric Rheumatology Symposium
A Pilot Randomized Controlled Trial of the iCanCope Pain Self-management Application for Adolescents with Juvenile Idiopathic Arthritis
Background/Purpose: Pain is the most common symptom of Juvenile Idiopathic Arthritis (JIA), a chronic childhood illness that has potentially debilitating effects on health-related quality of…
- 1
- 2
- 3
- …
- 19
- Next Page »